Advanz Pharma has acquired the global rights (except in Japan) to market Salagen (pilocarpine hydrochloride) tablets, an approved therapy…
Patricia Inácio, PhD
Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Patricia Inácio, PhD
The Hungarian regulatory authority has agreed to extend the label of Wize Pharma‘s LO2A eye drops to include the treatment of…
Lower levels of Gαq — a protein that regulates many aspects of immune responses — appear to drive the progression of…
Although rare, localized amyloidosis can sometimes appear as a consequence of Sjogren’s syndrome, according to a case report from South…
Oral Health of Primary Sjögren’s Patients Seen as Similar to That of Healthy Controls in Small Study
The oral health of patients with primary Sjögren’s syndrome is similar to that of patients with rheumatoid arthritis or healthy individuals,…
Patients with primary Sjögren’s syndrome and joint inflammation are significantly more likely to have severe or very severe dry eye, according to…
Sjogren’s Patients Open to Tailored Therapy to Improve Sleep Problems, Fatigue, Pain, Study Shows
Sleep problems are common in primary Sjogren’s syndrome patients and seem to worsen symptoms of fatigue and pain, affecting…
In rare cases, patients with Sjögren’s syndrome may develop an unusual degradation of the kidney’s filtering system — a…
Wize Pharma has enrolled the first participant in a Phase 4 clinical trial investigating the company’s LO2A drops to prevent…
A history of infection with nontuberculous mycobacteria — linked to chronic pulmonary infections, but unable to cause tuberculosis — may…